As part of the first stage of the advertising campaign, the ad is scheduled to appear in the News-Sun over another two weekends and you will be followed by further public awareness-raising efforts. The advocacy advertisement blasts Abbott for charging Mexico five occasions more than other middle-income countries because of its key AIDS medication, Kaletra. By exploiting patent protections in the UNITED STATES Free Trade Agreement , Abbott is able to charge Mexico $5,400 a complete year for Kaletra, a key second-line treatment for people living with HIV/AIDS, while charging $1,000 per year in Brazil-a country with a similar economy to Mexico. In the advertisement, AHF calls on Abbott to lower the price of Kaletra in Mexico to the price offered in Brazil. Abbott is definitely once more living up to its awful record on Helps by abusing NAFTA’s patent protections to charge five instances as very much for Kaletra in Mexico as it does in other middle-income countries, a heartless business calculation that efficiently makes this medication all but out of reach for nearly all those coping with HIV/AIDS in Mexico, said Michael Weinstein, AIDS Healthcare Base President.Piper Cancer Center Clinical Trials, a partnership of Scottsdale TGen and Health care. This is a new standard for treatment of metastatic pancreatic tumor that could become the backbone for additional brand-new treatment regimens, stated Dr. Von Hoff, echoing the analysis he presented earlier this year at the annual conference of the American Society of Clinical Oncology . The fact that Abraxane plus gemcitabine demonstrated a standard survival benefit is a significant step forward in offering new expect our sufferers. Dr. Von Hoff was the main Investigator of MPACT , the Phase III scientific study of 861 malignancy sufferers at 121 sites in North America, Europe and Australia.5 months, from 6.7 months.